TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15328178

Group type: EXPERIMENTAL
Intervention: Arzoxifene 10 mg daily
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Arzoxifene 20 mg daily
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Arzoxifene 50 mg daily
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 11276035

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10221828

Group type: EXPERIMENTAL
Intervention: sucralfate granules in suspension
Number of subjects: 52

Group type: COMPARATOR
Intervention: antacid
Number of subjects: 52
Study: 8174988

Group type: EXPERIMENTAL
Intervention: Intralipid 20% (6 g/h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg/kg/h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intraduodenal fat
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loxiglumide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 3591723

Group type: EXPERIMENTAL
Intervention: High-fat diet (40% of energy from fat) with P:S ratio of 1.0
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-fat diet (40% of energy from fat) with P:S ratio of 0.3
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low-fat diet (20% of energy from fat) with P:S ratio of 1.0
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low-fat diet (20% of energy from fat) with P:S ratio of 0.3
Number of subjects: 31
Study: 29790457

Group type: EXPERIMENTAL
Intervention: Busulfan/Fludarabine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Modified Busulfan/Cyclophosphamide
Number of subjects: 20
Study: 28169914

Group type: EXPERIMENTAL
Intervention: Slow-paced respiration
Number of subjects: 121
Study: 26260776

Group type: EXPERIMENTAL
Intervention: CRT with tegafur/gimeracil/oteracil (S‐1 group, n=30)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: CRT with tegafur‐uracil (UFT group, n=29)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: S‐1 group
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: UFT group
Number of subjects: 59
Study: 23924229

Group type: EXPERIMENTAL
Intervention: Generic feedback strategy using cumulative End‐of‐Life in Dementia (EOLD) scores of a group of patients
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Patient specific feedback strategy using EOLD scores on a patient level
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study: 21424576

Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet (30% energy)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Usual Protein (UP) diet (15% energy)
Number of subjects: 23
Study: 19069030

Group type: EXPERIMENTAL
Intervention: START triage method (colors: green, yellow, red, black)
Number of subjects: 98
Study: 16911173

Group type: EXPERIMENTAL
Intervention: Comprehensive group rehabilitation program (psychology-based education, exercise, peer support)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 55
Study: 12679918

Group type: EXPERIMENTAL
Intervention: Pre-operative radiochemotherapy (40-46 Gy + 5-FU + LV and 5'-DFuR)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Preoperative radiotherapy (40-50 Gy) + surgery
Number of subjects: 15
Study: 10898185

Group type: EXPERIMENTAL
Intervention: mesna
Number of subjects: 58

Group type: COMPARATOR
Intervention: saline solution
Number of subjects: 58
Study: 8929261

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1556754

Group type: EXPERIMENTAL
Intervention: Conjoint therapy
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Concurrent therapy
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Individual therapy
Number of subjects: 356

Group type: COMPARATOR
Intervention: Providing efficacy information about alternative formats
Number of subjects: 356
Study: 3890528

Group type: EXPERIMENTAL
Intervention: 75 mg of dipyridamole for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 0
Study: 29883479

Group type: EXPERIMENTAL
Intervention: Deprexis (internet-based intervention for depression)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 140
Study: 27871433

Group type: EXPERIMENTAL
Intervention: HIC hospitals
Number of subjects: 94

Group type: COMPARATOR
Intervention: MIC hospitals
Number of subjects: 94
Study: 25342212

Group type: EXPERIMENTAL
Intervention: Prasugrel (20/3.75 mg, loading/maintenance dose)
Number of subjects: 742

Group type: COMPARATOR
Intervention: Clopidogrel (300/75 mg)
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 742

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 742
Study: 23277121

Group type: EXPERIMENTAL
Intervention: Brucella melitensis strain Rev. 1 vaccine (10(6) or 5 × 10(5) live cells)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Brucella melitensis strain Rev. 1 vaccine (7.5 × 10(6) organisms)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-vaccinated ewes
Number of subjects: 51
Study: 20973359

Group type: EXPERIMENTAL
Intervention: Cobalt-chromium femoral component
Number of subjects: 37

Group type: COMPARATOR
Intervention: Oxidized zirconium femoral component (Control)
Number of subjects: 37
Study: 18442345

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg BID
Number of subjects: 2052

Group type: COMPARATOR
Intervention: Bupropion SR 150 mg BID
Number of subjects: 2052

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2052
Study: 15995093

Group type: EXPERIMENTAL
Intervention: Financial incentive of 25 dollars for completing HIV counseling and testing
Number of subjects: 372

Group type: COMPARATOR
Intervention: No financial incentive (control periods)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Overall completion of HIV counseling and testing
Number of subjects: 372
Study: 12375675

Group type: EXPERIMENTAL
Intervention: Diet therapy and insulin as required
Number of subjects: 0

Group type: COMPARATOR
Intervention: No specific treatment
Number of subjects: 0
Study: 10357958

Group type: EXPERIMENTAL
Intervention: Cryopreservation of all obtained pronucleate embryos (n = 58)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Fresh embryo transfers (n = 67)
Number of subjects: 125
Study: 7579000

Group type: EXPERIMENTAL
Intervention: glipizide (2.5 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: antipyrine (20 mg/kg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: coumarin (5 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: self‐monitored blood glucose (SMBG) by glucometer
Number of subjects: 17
Study: 1657526

Group type: EXPERIMENTAL
Intervention: Long-term drug therapy (specific drug not mentioned)
Number of subjects: 0
Study: 7169142

Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate (ISDN) and Intra-Aortic Balloon Counterpulsation (IABCP)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Isosorbide Dinitrate (ISDN) alone
Number of subjects: 7
Study: 30804314

Group type: EXPERIMENTAL
Intervention: Aegis™ sealant
Number of subjects: 34

Group type: COMPARATOR
Intervention: Embrace Wetbond™ sealant
Number of subjects: 34
Study: 29149745

Group type: EXPERIMENTAL
Intervention: Ethanol users (B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Natural gas users (C)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Firewood/kerosene users (A)
Number of subjects: 48
Study: 27043535

Group type: EXPERIMENTAL
Intervention: EPO+G-CSF
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 25594755

Group type: EXPERIMENTAL
Intervention: Triple therapy plus bismuth subsalicylate
Number of subjects: 54

Group type: COMPARATOR
Intervention: Triple therapy plus placebo
Number of subjects: 54
Study: 23047592

Group type: EXPERIMENTAL
Intervention: E‐CMF (epirubicin followed by cyclophosphamide, methotrexate and fluorouracil)
Number of subjects: 2391

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate and fluorouracil)
Number of subjects: 2391
Study: 20018946

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 17): face‐to‐face counseling at the first visit, four telephone calls, a video highlighting personal stories, and a cessation guide.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (n = 18): brief face‐to‐face counseling at the first visit and written materials.
Number of subjects: 35
Study: 17714570

Group type: EXPERIMENTAL
Intervention: Ketamine with intravenous patient-controlled-analgesia morphine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 42
Study: 15902927

Group type: EXPERIMENTAL
Intervention: Cypher sirolimus‐eluting stent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taxus paclitaxel‐eluting stent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 0
Study: 12296509

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg/day)
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg/day)
Number of subjects: 29133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29133
Study: 10101629

Group type: EXPERIMENTAL
Intervention: Harpagophytum extract WS 1531 (600 mg)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Harpagophytum extract WS 1531 (1200 mg)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 7791062

Group type: EXPERIMENTAL
Intervention: AMO Vitrax
Number of subjects: 95

Group type: COMPARATOR
Intervention: Healon
Number of subjects: 95
Study: 2170884

Group type: EXPERIMENTAL
Intervention: Estrone sulfate 0.625 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrone sulfate 1.25 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 328209

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 31291491

Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound thalamotomy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound subthalamotomy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound pallidotomy
Number of subjects: 62
Study: 28574528

Group type: EXPERIMENTAL
Intervention: Self-reporting of etiquette behaviors every 2 weeks for 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm received questions on quality improvement behaviors
Number of subjects: 0
Study: 25271354

Group type: EXPERIMENTAL
Intervention: Valsartan and moxonidine (group VM)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide and amlodipine (group BA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (healthy age-matched)
Number of subjects: 42
Study: 23782814

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus erlotinib
Number of subjects: 451

Group type: COMPARATOR
Intervention: Chemotherapy plus placebo
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus erlotinib (in patients with activating EGFR gene mutation)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Chemotherapy plus placebo (in patients with activating EGFR gene mutation)
Number of subjects: 451
Study: 22151975

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (800 IU of vitamin D and 1000 mg of calcium daily)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 704
Study: 19427094

Group type: EXPERIMENTAL
Intervention: Isobaric laparoscopic assisted minilaparotomy myomectomy (LM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Minilaparotomy (MLT)
Number of subjects: 80
Study: 16989901

Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (32 mg/day)
Number of subjects: 685

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 685
Study: 14627173

Group type: EXPERIMENTAL
Intervention: Adjustable dosing with budesonide/formoterol (Symbicort, Turbuhaler) 80/4.5 microg or 160/4.5 microg, two inhalations twice daily for four weeks, followed by adjustable maintenance dosing for six months
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Fixed dosing with budesonide/formoterol (Symbicort, Turbuhaler)
Number of subjects: 1034
Study: 16212331

Group type: COMPARATOR
Intervention: Microdiscectomy only (MDO)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Microdiscectomy followed by autologous bone graft (ABG)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Microdiscectomy followed by polymethylmethacrylate (PMMA)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Microdiscectomy followed by threaded titanium cage (TTC)
Number of subjects: 125
Study: 9703286

Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cyclophosphamide/cisplatin
Number of subjects: 45
Study: 9173128

Group type: EXPERIMENTAL
Intervention: Low dose heparin (15,000 units)
Number of subjects: 3540

Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 3540
Study: 2915651

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (six cycles of cyclophosphamide 100 mg/m² orally on days 1-14, methotrexate 40 mg/m² intravenously on days 1 and 8, fluorouracil 600 mg/m² intravenously on days 1 and 8, and prednisone 40 mg/m² orally on days 1-14)
Number of subjects: 536

Group type: COMPARATOR
Intervention: No-treatment observation (Control)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 536
Study: 951456

Group type: EXPERIMENTAL
Intervention: Amphetamine formulations
Number of subjects: 0
Study: 30817402

Group type: EXPERIMENTAL
Intervention: Restrictive red blood cell transfusion threshold (7 g/dl)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fresh-frozen plasma and platelets during burn excision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion practice during burn excision and grafting
Number of subjects: 0
Study: 29390308

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 611

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 611
Study: 24983993

Group type: EXPERIMENTAL
Intervention: Onlay mesh augmentation (OMA)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Primary suture
Number of subjects: 480

Group type: COMPARATOR
Intervention: Sublay mesh augmentation
Number of subjects: 480
Study: 23571642

Group type: EXPERIMENTAL
Intervention: Multidisciplinary foot-care program (12 months, involving a paediatric rheumatologist, podiatrist, physiotherapist, and musculoskeletal ultrasonographer)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard medical care (usual care)
Number of subjects: 44
Study: 22052161

Group type: EXPERIMENTAL
Intervention: Collaborative learning method
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Individualistic learning method
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Overall intervention (both methods)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Collaborative vs Individualistic learning
Number of subjects: 146
Study: 19352162

Group type: EXPERIMENTAL
Intervention: Epidural lidocaine (10 ml, 1%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combined spinal-epidural anesthesia (CSEA)
Number of subjects: 60
Study: 16672092

Group type: EXPERIMENTAL
Intervention: Closed-loop group (propofol titration using a proportional differential algorithm)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Target control infusion (TCI) group (manual propofol titration guided by Bispectral Index using Diprifusor device)
Number of subjects: 40
Study: 14754826

Group type: EXPERIMENTAL
Intervention: Educational intervention designed to encourage graded activity
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (initially not receiving the intervention)
Number of subjects: 114
Study: 11358728

Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg/g ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcipotriol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tacalcitol
Number of subjects: 0

Group type: COMPARATOR
Intervention: White petrolatum
Number of subjects: 0
Study: 9143797

Group type: EXPERIMENTAL
Intervention: Extended Wear (EW)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Daily Wear (DW)
Number of subjects: 134
Study: 29510425

Group type: EXPERIMENTAL
Intervention: Peanut ball device
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Peanut ball device (subgroup with labor arrest)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care (subgroup with labor arrest)
Number of subjects: 96
Study: 27118225

Group type: EXPERIMENTAL
Intervention: HFPEF
Number of subjects: 90
Study: 25447749

Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation (GVS) with cathode-right
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation (GVS) with cathode-left
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 4
Study: 23845729

Group type: EXPERIMENTAL
Intervention: Isometric‐eccentric‐isometric contractions
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Purely isometric contractions
Number of subjects: 13
Study: 19392925

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 13110

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 13110

Group type: COMPARATOR
Intervention: Losartan 100 mg
Number of subjects: 13110

Group type: COMPARATOR
Intervention: Irbesartan 150 mg
Number of subjects: 13110

Group type: COMPARATOR
Intervention: Candesartan 16 mg
Number of subjects: 13110
Study: 17219280

Group type: EXPERIMENTAL
Intervention: Left lateral internal sphincterotomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 50
Study: 15499528

Group type: EXPERIMENTAL
Intervention: CVD 1204 (10^7, 10^8, or 10^9 cfu)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CVD 1208 (10^7, 10^8, or 10^9 cfu)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CVD 1204
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CVD 1208
Number of subjects: 44
Study: 11794731

Group type: EXPERIMENTAL
Intervention: Heat conditioning before induction of hyperalgesia (45 degrees C for 5 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heat conditioning after induction of hyperalgesia (2 degrees C above individual pain threshold)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No heat conditioning (control)
Number of subjects: 0
Study: 9484362

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (IVMP; 1 g daily for 6 days) during rIFN beta‐1a treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (IVMP; 1 g daily for 6 days) without rIFN beta‐1a treatment
Number of subjects: 29
Study: 8038592

Group type: EXPERIMENTAL
Intervention: TNF, interferon‐gamma (IFN‐gamma), and melphalan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose TNF in isolated limb perfusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TNF, IFN, and melphalan limb perfusion with systemic high-dose interleukin-2 postoperatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard melphalan-alone perfusion
Number of subjects: 0
Study: 2924980

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily for 8 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Terbinafine 500 mg daily for 8 days
Number of subjects: 10
Study: 241876

Group type: EXPERIMENTAL
Intervention: Propranolol (50 mg three times daily for 4 weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prindolol (10 mg three times daily)
Number of subjects: 8
Study: 30353406

Group type: EXPERIMENTAL
Intervention: Early NG tube removal (removed on postoperative day 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional NG tube removal (removed on postoperative day 7)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Early NG tube removal
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional NG tube removal
Number of subjects: 80
Study: 28646182

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MCT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 45
Study: 26314605

Group type: EXPERIMENTAL
Intervention: Embrace WetBond sealant
Number of subjects: 34

Group type: COMPARATOR
Intervention: Helioseal sealant
Number of subjects: 34
Study: 23448100

Group type: EXPERIMENTAL
Intervention: Targeted intervention
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Enhanced Tailored intervention
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 3000
Study: 21320087

Group type: EXPERIMENTAL
Intervention: LMA Fastrach
Number of subjects: 154

Group type: COMPARATOR
Intervention: Air-Q
Number of subjects: 154
Study: 17932248

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate therapy
Number of subjects: 454
Study: 17870476

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Inclined position (45 degrees)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Upright position (90 degrees)
Number of subjects: 75
Study: 15118645

Group type: EXPERIMENTAL
Intervention: First trimester ultrasound screening
Number of subjects: 218

Group type: COMPARATOR
Intervention: Second trimester ultrasound screening
Number of subjects: 218
Study: 11673142

Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (HS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cold Steel Scalpel (CSS)
Number of subjects: 0
Study: 9196522

Group type: EXPERIMENTAL
Intervention: Induced sputum
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bronchial washings
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bronchoalveolar lavage (BAL) fluid
Number of subjects: 16
Study: 7835803

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus a platinum compound
Number of subjects: 0